This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Resumen de acción DP81
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de Diffusion Pharmaceuticals Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.70 |
| 52 Week High | US$11.87 |
| 52 Week Low | US$5.25 |
| Beta | 1.81 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -53.28% |
| 3 Year Change | -65.66% |
| 5 Year Change | -98.49% |
| Change since IPO | -99.38% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| DP81 | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | 0% | -4.9% | -1.5% |
| 1Y | -53.3% | -19.9% | 0.9% |
Rentabilidad vs. Industria: DP81 underperformed the German Biotechs industry which returned 3.3% over the past year.
Rentabilidad vs. Mercado: DP81 underperformed the German Market which returned -9.8% over the past year.
Volatilidad de los precios
| DP81 volatility | |
|---|---|
| DP81 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: DP81 has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine DP81's volatility change over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2001 | 16 | Bob Cobuzzi | www.diffusionpharma.com |
Resumen de fundamentos de Diffusion Pharmaceuticals Inc.
| Estadísticas fundamentales de DP81 | |
|---|---|
| Capitalización bursátil | €12.52m |
| Beneficios(TTM) | -€13.98m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-0.9x
Ratio precio-beneficio (PE)¿Está DP81 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de DP81 | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$14.99m |
| Beneficios | -US$14.99m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -7.35 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado DP81 a largo plazo?
Ver rendimiento histórico y comparativa